Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons

References

• Maruschak LM, Bronson J, Alper M. Alcohol and drug use and treatment reported by prisoners: survey of prison inmates, 2016. 2021. https://www.ojp.gov/library/publications/alcohol-and-drug-use-and-treatment-reported-prisoners-survey-prison-inmates
   Google Scholar
• Mital S, Wolff J, Carroll JJ. The relationship between incarceration history and overdose in North America: a scoping review of the evidence. Drug Alcohol Depend. 2020;213:108088.
   PubMed Web of Science ®Google Scholar
• Pew Charitable Trusts. Opioid use disorder treatment in jails and prisons: medication provided to incarcerated populations saves lives. 2020. https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2020/04/opioid-use-disorder-treatment-in-jails-and-prisons. Accessed September 24, 2021.
   Google Scholar
• Doernberg M, Krawczyk N, Agus D, Fingerhood M. Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis? Subst Abus. 2019;40(2):148–153.
   PubMed Web of Science ®Google Scholar
• Grella CE, Ostile E, Scott CK, Dennis M, Carnavale J. A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system. Int J Drug Policy. 2020;81:102768.
   PubMed Web of Science ®Google Scholar
• Komalasari R, Wilson S, Haw S. A systematic review of qualitative evidence on barriers to and facilitators of the implementation of opioid agonist treatment (OAT) programmes in prisons. Int J Drug Policy. 2021;87:102978.
   PubMed Web of Science ®Google Scholar
• Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–407.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction. 2008;103(8):1333–1342.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33–40.
   PubMed Web of Science ®Google Scholar
• Rich JD, McKenzie M, Larney S, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386(9991):350–359.
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole S, Yu E, Carroll J, Lynch KG. Extended release injectable naltrexone before vs. after release: a randomized trial of opioid addicted persons who are in prison. J Subst Abuse Treat. 2021;127:108355.
   PubMed Web of Science ®Google Scholar
• Moore KE, Roberts W, Reid HH, Smith KMZ, Oberleitner LMS, McKee SA. Effectiveness of medication assisted treatment for opioid use in prison and jail settings: a meta-analysis and systematic review. J Subst Abuse Treat. 2019;99:32–43.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE, Fitzgerald TT, Vocci FJ. A randomized clinical trial of buprenorphine for prisoners: findings at 12-months post-release. Drug Alcohol Depend. 2017;172:34–42.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, Mitchell SG, et al. Randomized trial of methadone treatment of arrestees: 24-month post-release outcomes. Drug Alcohol Depend. 2021;218:108392.
   PubMed Web of Science ®Google Scholar
• Brezel ER, Powell T, Fox AD. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated. Subst Abus. 2020;41(2):150–154.
   PubMed Web of Science ®Google Scholar
• National Academy for State Health Policy. Medications for Opioid Use Disorder (MOUD) provided in state prisons. https://www.nashp.org/nashp-chart-medications-for-opioid-use-disorder-provided-in-state-prisons-march-2021/ Published March 2021. Accessed September 24, 2021.
   Google Scholar
• Sufrin C, Sutherland L, Beal L, Terplan M, Latkin C, Clarke JG. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study. Addiction. 2020;115(11):2057–2065.
   PubMed Web of Science ®Google Scholar
• Curtis M, Larney S, Higgs P, et al. Initiation of medications for opioid use disorder shortly before release from prison to promote treatment retention: strong evidence but compromised policy. J Addict Med. 2021;15(6):525–526.
   PubMed Web of Science ®Google Scholar
• Zgoba KM, Reeves R, Tamburello A, Debilio L. Criminal recidivism in inmates with mental illness and substance use disorders. J Am Acad Psychiatry Law. 2020;48(2):209–215.
   PubMed Web of Science ®Google Scholar
• Cioe K, Biondi BE, Easly R, Simard A, Zheng X, Springer SA. A systematic review of patients' and providers’ perspectives of medications for treatment of opioid use disorder. J Subst Abuse Treat. 2020;119:108146.
   PubMed Web of Science ®Google Scholar
• Larney S, Zador D, Sindicich N, Dolan K. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia: opioid substitution treatment in prison. Drug Alcohol Rev. 2017;36(3):305–310.
   PubMed Web of Science ®Google Scholar
• Mukherjee TI, Wickersham JA, Desai MM, Pillai V, Kamarulzaman A, Altice FL. Factors associated with interest in receiving prison-based methadone maintenance therapy in Malaysia. Drug Alcohol Depend. 2016;164:120–127.
   PubMed Web of Science ®Google Scholar
• Maradiaga JA, Nahvi S, Cunningham CO, Sanchez J, Fox AD. “I kicked the hard way. I got incarcerated.” Withdrawal from methadone during incarceration and subsequent aversion to medication assisted treatments. J Subst Abuse Treat. 2016;62:49–54.
   PubMed Web of Science ®Google Scholar
• Velasquez M, Flannery M, Badolato R, et al. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addict Sci Clin Pract. 2019;14(1):37.
   PubMed Web of Science ®Google Scholar
• Vail W, Faro E, Watnick D, Giftos J, Fox AD. Does incarceration influence patients' goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail. Drug Alcohol Depend. 2021;222:108529.
   PubMed Web of Science ®Google Scholar
• Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2.
   PubMedGoogle Scholar
• Kaplowitz E, Truong AQ, Macmadu A, et al. Fentanyl-related overdose during incarceration: a comprehensive review. Health Justice. 2021;9(1):13.
   PubMedGoogle Scholar
• Swarbrick M, Bohan MC, Gitlitz R, Hillis M. Peer health navigators support individuals with an opioid use disorder transitioning from prison. Drug Alcohol Depend. 2019;203:88–91.
   Web of Science ®Google Scholar
• State of New Jersey. Governor Murphy signs legislation requiring public health emergency credits to be awarded to certain inmates and parolees during a public health emergency. https://www.nj.gov/governor/news/news/562020/20201019c.shtml. Published October 19, 2020. Accessed September 24, 2021.
   Google Scholar
• Patton M. Qualitative research & evaluation methods. SAGE Publications Inc. https://us.sagepub.com/en-us/nam/qualitative-research-evaluation-methods/book232962. Published August 7, 2020. Accessed August 11, 2020.
   Google Scholar
• Brinkley-Rubinstein L, Peterson M, Clarke J, et al. The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting. Drug Alcohol Depend. 2019;205:107514.
   PubMed Web of Science ®Google Scholar
• Sharp A, Carlson M, Howell V, Moore K, Schuman-Olivier Z. Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida. J Subst Abuse Treat. 2021;123:108247.
   PubMed Web of Science ®Google Scholar
• Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: a systematic review. Subst Use Misuse. 2021;56(14):2181–2201.
   PubMed Web of Science ®Google Scholar
• Binswanger IA, Nowels C, Corsi KF, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7(1):3.
   PubMedGoogle Scholar
• Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–1242.
   PubMed Web of Science ®Google Scholar
• Coulter A, Ellins J. Effectiveness of strategies for informing, educating, and involving patients. Bmj. 2007;335(7609):24–27.
   PubMed Web of Science ®Google Scholar
• Banta-Green CJ, Williams JR, Sears JM, Floyd AS, Tsui JI, Hoeft TJ. Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder. Drug Alcohol Depend. 2020;207:107799.
   PubMed Web of Science ®Google Scholar
• Mooney LJ, Valdez J, Cousins SJ, Yoo C, Zhu Y, Hser YI. Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): rationale, methodology, and preliminary results. J Subst Abuse Treat. 2020;108:115–122.
   PubMed Web of Science ®Google Scholar
• South J, Bagnall AM, Woodall J. Developing a typology for peer education and peer support delivered by prisoners. J Correct Health Care. 2017;23(2):214–229.
   PubMed Web of Science ®Google Scholar
• Sweeney S, Cunningham S, Quijano A, Verrelli A, Mukherji R. New Jersey Senate Bill S2953. 2021. https://www.njleg.state.nj.us/bills/BillView.asp?BillNumber=S2519
   Google Scholar
• Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. Buprenorphine in the United States: motives for abuse, misuse, and diversion. J Subst Abuse Treat. 2019;104:148–157.
   PubMed Web of Science ®Google Scholar
• McLean K. “There’s nothing here”: deindustrialization as risk environment for overdose. Int J Drug Policy. 2016;29:19–26.
   PubMed Web of Science ®Google Scholar
• Gryczynski J, Lee JD, Dusek K, et al. Use of non–prescribed buprenorphine in the criminal justice system: perspectives of individuals recently released from incarceration. J Subst Abuse Treat. 2021;127:108349.
   PubMed Web of Science ®Google Scholar
• Monico LB, Gryczynski J, Lee JD, et al. Exploring nonprescribed use of buprenorphine in the criminal justice system through qualitative interviews among individuals recently released from incarceration. J Subst Abuse Treat. 2021;123:108267.
   PubMed Web of Science ®Google Scholar
• White N, Ali R, Larance B, Zador D, Mattick RP, Degenhardt L. The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film. Drug Alcohol Rev. 2016;35(1):76–82.
   PubMed Web of Science ®Google Scholar
• Sud A, Salamanca-Buentello F, Buchman DZ, Sabioni P, Majid U. Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs’ perspectives of and experiences with the extramedical use and diversion of buprenorphine. J Subst Abuse Treat. 2022;135:108651.
   PubMedGoogle Scholar